HHS, other agencies fail to meet IT goals

The Department of Health & Human Services (HHS) and four other federal agencies have failed to meet incremental development requirements for their IT projects, according to a report from the Government Accountability Office (GAO).

Federal agencies previously had to deliver IT investment capabilities every 12 months, but they now are required to do so every six months. 

The GAO tracked IT development at five federal agencies: Department of Defense; Department of Homeland Security; Department of Transportation; Department of Veterans Affairs (VA); and HHS.

All five agencies had developed policies that address incremental development, but only VA addressed the three components necessary for implementing the Office of Budget and Management's guidance on such development, according to the report. The components include: requiring delivery of functionality every six months; defining functionality; and defining a compliance enforcement process.

Nearly three-quarters of IT investments made by the five federal agencies were not on schedule to deliver functionality within six months and fewer than half of IT investments were on schedule to deliver functionality within 12 months.

VA was marked for all of the factors associated with inhibiting IT development progress except for procurement delays of development schedules and technology selection. HHS was marked on all but one of the factors associated with inhibiting IT development progress, including late funding, failure to prioritize requirements and procurement delays.

HHS was not cited for a lack of supervision or governance.

The report concluded that without "consistent use of incremental development approaches, [IT] expenditures are more likely to continue to produce disappointing results."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.